Hoffmann-La Roche
Satralizumab
NMDAR Autoimmune Encephalitis
Countdown
162days
Phase 3 readout · Dec 16, 2026
What's at stake
Phase 3 trial results for Satralizumab in NMDAR Autoimmune Encephalitis are due Dec 16, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· ClinicalTrials.gov
verified 15h ago
“CT.gov NCT05503264: Phase 3 trial, sponsor Hoffmann-La Roche, drug Satralizumab. Primary completion date 2026-12-16 (estimated).”